Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierIncyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct discovery, clinical development and commercial operations. We also conduct clinical development and commercial operations from our European headquarters in Morges, Switzerland, and our other offices across Europe, as well as our Japanese headquarters in Tokyo and our Canadian headquarters in Montreal.
In the company’s own words · 10-K filed Feb 10, 2026 · SEC EDGAR
Business segments
Q2 2026 · $1.72BThe company’s own SEC segment disclosure.
- JAKAFI$816.7M48%
- OPZELURA$449.7M26%
- JAKAVI Royalty$124.2M7%
- NIKTIMVO$60.3M4%
- MINJUVIMONJUVI$53.7M3%
- ZYNYZ$49.9M3%
- Other (8)$164.7M10%
Incyte (INCY) reported revenue of $1.27B in Q1 2026 (quarter ended March 31, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 92% and net income of $303M (24% of revenue). For the full year FY2025, revenue was $5.14B (+21% year on year) and net income $1.29B. Its largest product in 2026-Q2 was JAKAFI at $817M, 48% of the disclosed total, just ahead of OPZELURA at 26%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Biotechnology
Ranks #2 of 145 by Smart Score